Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold
OncLive,
Joseph Ferra Elevation Oncology is pausing development of the human anti–HER3 IgG2 monoclonal antibody seribantumab, along with…
泛实体瘤疗法再添一员！FDA加速批准selpercatinib用于RET融合实体瘤！
CN-Healthcare,
基因组驱动的精准医疗改变了许多实体瘤的治疗格局。近年来，一些疗法已被确定在特定分子生物标志物的设置下可产生具有临床意义的疗效（无论癌症类型如何），并获得监管机构的批准，这意味着泛实体瘤疗法的时代已经来临。这次，泛实体瘤疗法再添新成员：针对RET基因融合的se…
CRESTONE Data Signal Positive Start to Treat Rare NRG1 Fusions in Solid Tumors
OncLive,
Results of the phase 2 CRESTONE study have demonstrated the tolerable safety profile and efficacy of seribantumab for the…
Seribantumab Demonstrates Positive Response Rates, Tolerability in NRG1 Fusion+ Solid Tumors
OncLive,
In Partnership With: Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE…